Brief: Transgene/BioInvent: positive data regarding their BT-001 product
09/11/2021 13:08
Nov 9 (Reuters) - Transgene Sa TRNG.PA /BioInvent:
* TRANSGENE AND BIOINVENT PRESENT PRECLINICAL DATA
HIGHLIGHTING
THE ROBUST ANTI-TUMORAL ACTIVITY OF BT-001 ONCOLYTIC VIRUS AT
SITC 2021
* THIS LATEST DATA SUPPORT BT-001'S UNIQUE DUAL MODE OF
ACTION
* THIS DATA DEMONSTRATE HIGH INTRATUMORAL EXPRESSION OF AN
IMMUNE
CHECKPOINT-INHIBITING ANTIBODY AND ROBUST ANTI-TUMORAL ACTIVITY
IN SEVERAL TUMOR MODELS.
Source text for Eikon: ID:nBw5TlBq9a
Further company coverage: TRNG.PA
(Reporting by Sudip Kar-Gupta)
((sudip.kargupta@thomsonreuters.com;))